Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 Recruiting Phase 2 Trials for Avapritinib (DB15233)

IndicationStatusPhase
DBCOND0113388 (Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04771520Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid TumorsTreatment